Biotechnology company dedicated to discovering and developing transformative medicines for genetically defined diseases.
2seventy bio, Inc. is a pioneering cell and gene therapy company dedicated to advancing the frontier of cancer treatment within the United States. The company specializes in the research, development, and commercialization of innovative therapies designed to combat various forms of cancer.
At the forefront of its product pipeline are idecabtagene vicleucel, also known as ide-cel or Abecma, and bb21217. These cutting-edge CAR-T cell therapies represent promising advancements in the field, particularly for the treatment of multiple myeloma, a challenging hematologic malignancy.
2seventy bio, Inc. operates in collaboration with Bristol-Myers Squibb Company, leveraging strategic partnerships to enhance its capabilities in research, development, and clinical trials. This collaboration underscores the company's commitment to accelerating the availability of novel therapies that can potentially transform cancer treatment paradigms.
Founded in 2021 and headquartered in Cambridge, Massachusetts, 2seventy bio, Inc. is poised at the intersection of scientific innovation and clinical application. With a dedicated focus on advancing personalized medicine approaches through cell and gene therapies, the company aims to make significant strides in improving outcomes for patients grappling with cancer.